[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642337":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":10,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":10,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":82,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with Metastatic Breast Cancer",null,"This is a prospective cohort study of patients with Stage 4 (metastatic) breast cancer with brain metastases and\u002For leptomeningeal disease who are receiving treatment for cancer or cancer-related disease. Through a series of surveys, participants will be asked about race\u002Fmenopausal status, social determinants, symptom experience, and cognitive and physical functioning. Participants will be asked to update surveys every 3 months. Additional demographic and on-investigational \u002F routine care treatment information will be obtained from the Electronic Medical Record (EMR).",[13,14],"Other: Health-Related Quality of Life (QOL) questionnaires","Other: Medical Chart Review",[16,23],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"Health-Related Quality of Life (QOL) questionnaires","Participants can complete questionnaires online, via tablet in clinic, or via paper and pencil in clinic",[9],[21,22],"Health-Related Quality of Life (HrQOL) questionnaires","Symptom Questionnaire",{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Medical Chart Review","Data will be collected from the participants electronic medical record",[9],[28],"Medical Record Review",[30,33],{"name":31,"affiliation":5,"role":32},"Laura Huppert, MD","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":5,"role":32},"Michelle Melisko, MD",[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Amy Langdon","CONTACT","877-827-3222","Amy.DeLuca@ucsf.edu",[42],{"facility":5,"status":10,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"San Francisco","California","94143","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-122.41942,37.77493,{"lat":52,"lon":51},[55,56,58,59],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},{"name":10,"role":38,"phone":10,"phoneExt":10,"email":57},"cancertrials@ucsf.edu",{"name":31,"role":32,"phone":10,"phoneExt":10,"email":10},{"name":34,"role":32,"phone":10,"phoneExt":10,"email":10},{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642337","quality-of-life-for-patients-with-breast-cancer-brain-metastases-and-leptomeningeal-disease-100642337",false,"NCT07659652","Quality of Life for Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease","Prospective Evaluation of Quality of Life in Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease","Inclusion Criteria:\n\n1. Be male or female 18 years of age or older.\n2. Have stage 4 (metastatic) breast cancer with spread to the brain parenchyma and\u002For leptomeninges.\n3. Have the intention to start or continue anticancer therapy.\n4. Be able to provide informed consent.\n5. Be able to speak and read English.\n\nExclusion Criteria:\n\nParticipants who are not on any anticancer therapy and are not planning to start any anticancer therapy will be excluded from the study.","ALL","18 Years",{"count":72,"type":73},200,"ESTIMATED","OBSERVATIONAL","Central nervous system (CNS) metastases including breast cancer brain metastases (BCBMs) and leptomeningeal disease (LMD) are common affecting up to 30% of patients with metastatic breast cancer (MBC). The goal of this research is to understand symptom burden and quality of life trajectories in this population and how treatments guide care management decisions.",[77,78,79,80,81],"Breast Cancer, Quality of Life","Breast Cancer, Metastatic","Breast Cancer, Metastatic Breast Cancer","Leptomeningeal Metastasis of Breast Cancer","Brain Metastases From Breast Cancer",[83],"Quality of Life","NOT_YET_RECRUITING","2026-06-15",{"date":87,"type":88},"2026-06-22","ACTUAL",{"date":85,"type":73},{"date":91,"type":73},"2035-12-31",{"name":5,"class":6},1]